Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2016-10-09 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于本次非公开发行方案涉及关联交易事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a non-public issuance of shares involving related party transactions. It details the issuance plan, pricing, subscription agreements, board approvals, and independent director opinions. It is not a full financial report but a disclosure about a capital raising event and related party transaction. The document length is about 5,050 characters, and it contains detailed information about the transaction, pricing, and approvals, which fits the category of Capital/Financing Update (CAP). It is not an Annual Report, Interim Report, or Earnings Release, nor is it a simple announcement of a report publication. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-10-09 Chinese
独立董事关于非公开发行相关事项以及涉及关联交易的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from independent directors regarding a non-public issuance of A shares involving related party transactions. It references compliance with stock exchange listing rules, company articles, and relevant laws. The content focuses on the fairness, legality, and approval procedures of the issuance and related party transactions. It does not contain financial statements or detailed financial results, nor is it a report or announcement of financial results. It is a formal opinion related to capital raising activities and associated governance matters. Given the focus on non-public issuance and related party transactions, this fits best under Capital/Financing Update (CAP). The document length is short and it is not merely an announcement of a report, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2016-10-09 Chinese
独立董事关于调整后的非公开发行股票涉及关联交易的事前认可意见
Capital/Financing Update Classification · 95% confidence The document is a statement from independent directors regarding the fairness and reasonableness of an adjusted non-public stock issuance involving related party transactions. It references regulatory compliance and approval opinions but does not contain financial statements or detailed financial data. The document is short (691 characters) and serves as an official opinion or announcement related to a capital raising activity involving related parties. This fits best under Capital/Financing Update (CAP) as it concerns adjustments to a non-public stock issuance and related party transactions, which are financing activities.
2016-10-09 Chinese
关于2016年非公开发行股票后填补被摊薄即期回报措施（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding a non-public issuance of shares in 2016. It discusses the impact of the issuance on immediate shareholder returns, financial metrics such as earnings per share and return on equity, and the company's plans and commitments to mitigate dilution effects. It references regulatory approvals needed from the China Securities Regulatory Commission and compliance with various Chinese regulatory guidelines. The document includes detailed financial assumptions, risk disclosures, strategic rationale, and governance commitments related to the capital raising. This is a comprehensive disclosure about a capital raising event and its financial impact, not a full annual or interim report, nor a simple announcement of a report. It is not a certification or a voting result announcement. The content focuses on financing activities and capital structure changes, including the use of proceeds and risk management. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length (13,989 characters) and detailed financial analysis support that it is a substantive update rather than a brief announcement or regulatory filing.
2016-10-09 Chinese
关于非公开发行A股股票预案修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding revisions to its non-public issuance of A shares plan. It details changes in the number of shares to be issued, the amount of funds to be raised, and the investment projects for the raised funds. The document is a formal announcement about financing activities, specifically about a capital raising plan revision. It does not contain full financial statements or comprehensive financial performance data, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive content about the financing plan changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2016-10-09 Chinese
关于最近五年未被证券监管部门和交易所采取处罚或监管措施的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. stating that in the past five years, the company has not been subject to any penalties or regulatory measures by securities regulatory authorities or exchanges. It mentions a planned non-public issuance of A-shares but does not provide financial data or detailed report content. The document is only 524 characters long and serves as a regulatory compliance disclosure related to the company's legal and regulatory status. It does not contain financial statements, management discussion, or detailed report information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-10-09 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.